$SSY
SUNLINK HEALTH SYSTEMS INC

2021 Q2 Form 10-Q Financial Statement

#000156459021027833 Filed on May 14, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2021 Q1 2020 Q1
Revenue $10.34M $9.778M $12.67M
YoY Change -3.31% -22.81% 2.48%
Cost Of Revenue $3.944M $3.682M $5.370M
YoY Change -6.36% -31.43% -3.05%
Gross Profit $6.391M $6.096M $7.297M
YoY Change -1.33% -16.46% 6.96%
Gross Profit Margin 61.84% 62.34% 57.61%
Selling, General & Admin $1.993M $5.136M $6.158M
YoY Change -66.63% -16.6% 1.32%
% of Gross Profit 31.18% 84.25% 84.39%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $404.0K $339.0K $371.0K
YoY Change 2.54% -8.63% 1.09%
% of Gross Profit 6.32% 5.56% 5.08%
Operating Expenses $3.403M $6.636M $7.335M
YoY Change -50.17% -9.53% 0.34%
Operating Profit $2.988M -$540.0K -$38.00K
YoY Change -948.86% 1321.05% -92.21%
Interest Expense -$7.000K -$7.000K $10.00K
YoY Change 40.0% -170.0% -84.13%
% of Operating Profit -0.23%
Other Income/Expense, Net
YoY Change
Pretax Income $4.665M -$535.0K -$46.00K
YoY Change -1634.54% 1063.04% -91.65%
Income Tax $110.0K -$62.00K $0.00
% Of Pretax Income 2.36%
Net Earnings $4.687M -$531.0K -$158.0K
YoY Change -790.28% 236.08% -115.16%
Net Earnings / Revenue 45.35% -5.43% -1.25%
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share $659.0K -$76.87K -$0.02
COMMON SHARES
Basic Shares Outstanding 6.920M 6.956M
Diluted Shares Outstanding 6.956M

Balance Sheet

Concept 2021 Q2 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.962M $11.10M $4.003M
YoY Change -10.93% 177.24% -56.3%
Cash & Equivalents $9.962M $11.10M $4.003M
Short-Term Investments
Other Short-Term Assets $2.314M $1.968M $2.359M
YoY Change -9.54% -16.57% -11.45%
Inventory $1.890M $1.947M $2.102M
Prepaid Expenses
Receivables $4.189M $4.341M $5.677M
Other Receivables $3.586M $0.00 $0.00
Total Short-Term Assets $21.94M $19.35M $14.14M
YoY Change 10.13% 36.86% -25.88%
LONG-TERM ASSETS
Property, Plant & Equipment $6.554M $6.975M $6.499M
YoY Change 23.1% 7.32% 18.42%
Goodwill
YoY Change
Intangibles $1.227M
YoY Change -2.15%
Long-Term Investments
YoY Change
Other Assets $591.0K $515.0K $368.0K
YoY Change 18.2% 39.95% -54.34%
Total Long-Term Assets $9.623M $8.724M $8.133M
YoY Change 19.57% 7.27% 1.89%
TOTAL ASSETS
Total Short-Term Assets $21.94M $19.35M $14.14M
Total Long-Term Assets $9.623M $8.724M $8.133M
Total Assets $31.56M $28.08M $22.27M
YoY Change 12.85% 26.06% -17.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.096M $1.353M $1.908M
YoY Change 25.69% -29.09% 24.95%
Accrued Expenses $5.123M $4.767M $4.511M
YoY Change 11.1% 5.68% 1540.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.009M $1.272M $34.00K
YoY Change 114.78% 3641.18% -89.34%
Total Short-Term Liabilities $9.665M $8.949M $6.453M
YoY Change -15.34% 38.68% 6.84%
LONG-TERM LIABILITIES
Long-Term Debt $52.00K $2.060M $98.00K
YoY Change -97.34% 2002.04% -96.42%
Other Long-Term Liabilities $131.0K $166.0K $1.216M
YoY Change -9.03% -86.35% 415.25%
Total Long-Term Liabilities $1.089M $3.183M $1.314M
YoY Change -61.27% 142.24% -64.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.665M $8.949M $6.453M
Total Long-Term Liabilities $1.089M $3.183M $1.314M
Total Liabilities $10.75M $12.13M $7.767M
YoY Change -24.42% 56.2% -20.66%
SHAREHOLDERS EQUITY
Retained Earnings $6.809M $2.121M
YoY Change -8506.17%
Common Stock $14.16M $14.16M
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.81M $15.95M $14.51M
YoY Change
Total Liabilities & Shareholders Equity $31.56M $28.08M $22.27M
YoY Change 12.85% 26.06% -17.69%

Cashflow Statement

Concept 2021 Q2 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income $4.687M -$531.0K -$158.0K
YoY Change -790.28% 236.08% -115.16%
Depreciation, Depletion And Amortization $404.0K $339.0K $371.0K
YoY Change 2.54% -8.63% 1.09%
Cash From Operating Activities $167.0K $164.0K $143.0K
YoY Change -96.09% 14.69% -121.63%
INVESTING ACTIVITIES
Capital Expenditures -$1.296M $299.0K $336.0K
YoY Change 330.56% -11.01% 50.67%
Acquisitions
YoY Change
Other Investing Activities $3.000K $0.00 $0.00
YoY Change 200.0% -100.0%
Cash From Investing Activities -$1.293M -$299.0K -$336.0K
YoY Change 331.0% -11.01% -105.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K -8.000K -411.0K
YoY Change -100.31% -98.05% 596.61%
NET CHANGE
Cash From Operating Activities 167.0K 164.0K 143.0K
Cash From Investing Activities -1.293M -299.0K -336.0K
Cash From Financing Activities -10.00K -8.000K -411.0K
Net Change In Cash -1.136M -143.0K -604.0K
YoY Change -115.82% -76.32% -110.35%
FREE CASH FLOW
Cash From Operating Activities $167.0K $164.0K $143.0K
Capital Expenditures -$1.296M $299.0K $336.0K
Free Cash Flow $1.463M -$135.0K -$193.0K
YoY Change -67.99% -30.05% -78.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2558000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
19923000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
970000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
500000
CY2020Q2 us-gaap Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
2724000
CY2020Q2 us-gaap Assets
Assets
27971000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
872000
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1401000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1969000
CY2020Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
1411000
CY2020Q2 ssy Unearned Cares Act Funds
UnearnedCARESActFunds
4532000
CY2021Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
136000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
339000
CY2021Q1 ssy Federal Stimulus Provider Relief Funds
FederalStimulusProviderReliefFunds
11000
CY2020Q1 ssy Federal Stimulus Provider Relief Funds
FederalStimulusProviderReliefFunds
0
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-7000
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
10000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-24000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
14000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9778000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-21000
ssy Federal Stimulus Provider Relief Funds
FederalStimulusProviderReliefFunds
3459000
ssy Federal Stimulus Provider Relief Funds
FederalStimulusProviderReliefFunds
0
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
515000
CY2021Q1 us-gaap Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
3068000
CY2021Q1 us-gaap Assets
Assets
28078000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1353000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1319000
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
1272000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1984000
CY2021Q1 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
1824000
CY2021Q1 ssy Unearned Cares Act Funds
UnearnedCARESActFunds
1557000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
435000
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2060000
CY2021Q1 ssy Professional Liability Risks Non Current
ProfessionalLiabilityRisksNonCurrent
49000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
908000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
166000
CY2021Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3183000
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
3460000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
10704000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2121000
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-339000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
15946000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28078000
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q1 us-gaap Supplies Expense
SuppliesExpense
237000
CY2021Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6920000
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
524000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8949000
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
2000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6920000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-475000
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.03
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
2382000
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.03
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
14000
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.35
us-gaap Net Income Loss
NetIncomeLoss
2203000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2203000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-461000
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.00
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.34
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.00
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6976000
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.07
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6902000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
14507000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6995000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1198000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-300000
us-gaap Proceeds From Sale Of Other Assets Investing Activities
ProceedsFromSaleOfOtherAssetsInvestingActivities
40000
us-gaap Proceeds From Sale Of Other Assets Investing Activities
ProceedsFromSaleOfOtherAssetsInvestingActivities
558000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1259000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-326000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
25000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3025000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11184000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7742000
CY2021Q1 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-158000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-46000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2335000
CY2020Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
CY2020Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-46000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-540000
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-47000
CY2020Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-112000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-179000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-158000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2020Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.02
CY2020Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.02
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6956000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6948000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.32
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2020Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.01
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6956000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-340000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13403000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
3074000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
16477000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
15043000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-261000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28000
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
14810000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-42000
CY2019Q4 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
6000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
14762000
CY2020Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
97000
ssy Payments To Acquire Property Plant And Equipment Continuing Operations
PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations
1299000
ssy Payments To Acquire Property Plant And Equipment Continuing Operations
PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations
884000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
88000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-25000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3113000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-86000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3739000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11098000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4003000
ssy Interest Paid Received Net
InterestPaidReceivedNet
-1000
ssy Interest Paid Received Net
InterestPaidReceivedNet
74000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
293000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-43000
us-gaap Transfer To Other Real Estate
TransferToOtherRealEstate
0
us-gaap Transfer To Other Real Estate
TransferToOtherRealEstate
371000
us-gaap Stock Issued1
StockIssued1
10000
us-gaap Stock Issued1
StockIssued1
0
ssy Right Of Use Asset Obtained In Exchange For Lease Liability
RightOfUseAssetObtainedInExchangeForLeaseLiability
712000
ssy Right Of Use Asset Obtained In Exchange For Lease Liability
RightOfUseAssetObtainedInExchangeForLeaseLiability
1463000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2. &#8211; Business Operations </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SunLink Health Systems, Inc., through subsidiaries, owns businesses which are providers of healthcare services in certain markets in the United States. SunLink&#8217;s subsidiaries&#8217; businesses are composed of two business segments:</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Services</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">A subsidiary which owns and operates&#160;Trace Regional Hospital and Floy Dyer Nursing Home (&#8220;Trace&#8221;), an 84 licensed-bed acute care hospital, located in Houston, Mississippi, which includes an 26-bed geriatric psychology unit (&#8220;GPU&#8221;), and a 66-bed nursing home. This facility focuses primarily on senior healthcare services.</font>&#160; &#160;</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">A subsidiary, SunLink Health Systems Technology (&#8220;SHS Technology&#8221;), which provides information technology (IT) services to outside customers and to SunLink subsidiaries.</font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Symbol;"><font style="font-size:10pt;font-family:'Times New Roman'">A</font><font style="font-size:10pt;font-family:'Times New Roman'"> </font></font><font style="font-family:Times New Roman;">subsidiary which owns approximately five (5) acres of unimproved land in Houston, Mississippi.</font> </p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.12%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.12%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;<font style="font-family:Symbol;"><font style="font-size:10pt;font-family:'Times New Roman'">A</font><font style="font-size:10pt;font-family:'Times New Roman'"> </font></font>subsidiary which owns approximately 25 acres of unimproved land in Ellijay, Georgia.</p></td></tr></table></div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pharmacy</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pharmacy segment is composed of three operational areas which are conducted primarily in markets in &nbsp;&nbsp;&nbsp;&nbsp;south Louisiana:</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Retail pharmacy products and services, consisting of retail pharmacy sales conducted in Crowley, Louisiana. </font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as nursing homes, assisted living facilities, behavioral and specialty hospitals, hospice, and correctional facilities; and,</font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td> <td valign="top" style="width:4.25%;white-space:nowrap"> <p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#32;</font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#32;</font></p></td> <td valign="top"> <p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Durable medical equipment products and services (&#8220;DME&#8221;), consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care.</font></p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SunLink subsidiaries have conducted the Healthcare Services business since 2001 and the Pharmacy operations since 2008. Our Pharmacy segment currently is operated through Carmichael&#8217;s Cashway Pharmacy,&#160;Inc. (&#8220;Carmichael&#8221;), a subsidiary of our SunLink ScriptsRx, LLC subsidiary.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#212529;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">COVID-19 Pandemic</font></p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.91%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A novel strain of coronavirus (&#8220;COVID-19&#8221;) was declared a global pandemic by the World Health Organization on March 11, 2020. We have been monitoring the COVID-19 pandemic and its impact on our operations, and we have taken significant steps intended to minimize the risk to our employees and patients. Certain employees have been working remotely, but we believe these remote work arrangements have not materially affected our ability to maintain critical business operations, which are being conducted substantially in accordance with our understanding of applicable government health and safety protocols and guidance issued in response to the COVID-19 pandemic. Such government health and safety protocols and guidance are rapidly changing and, at times, unclear. Nevertheless, as in many healthcare environments, we have experienced COVID-19 illness, including deaths, and some employees have tested positive and were placed on leave or in quarantine. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:6.25%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In late December 2020, we began receiving allotments of COVID-19 vaccine and have vaccinated patients, providers, employees, and staff in accordance with the protocols and guidelines in the states where we operate that requested the vaccination.&nbsp;&nbsp;Not all such individuals have been vaccinated to date and some individuals have not consented to vaccination. We are also vaccinating members of the community that have requested a vaccination as we have COVID-19 vaccine available. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:6.25%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our Healthcare businesses, we have experienced material reductions in demand and lost revenues due to the COVID-19 outbreak. There has been minimal current demand for nursing home admissions, and clinic visits and hospital services have substantially decreased as well, in part due to the abrupt retirement of one physician in the quarter ended June 30, 2020 and reduced capacity of other physicians and providers, all as a result of the effects of the pandemic. The availability and cost of medical supplies have adversely affected our Healthcare businesses during much of the pandemic, especially with respect to access to personal protective equipment, cleaning supplies and COVID-19 testing materials, which continue to be more expensive compared to pre-pandemic prices. We continue to monitor supplies and seek additional sources of many supply items. A reduction in the availability of qualified employees has also occurred and despite good faith efforts to do so, we have not yet been able to rehire or fully replace staff reductions which were previously furloughed, laid off or retired.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.91%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the beginning of the COVID-19 pandemic, our Pharmacy business has experienced reduced sales trends in certain areas, increased costs, and reduced staff.&nbsp;&nbsp;Many of our primary physician referral sources have been operating at substantially reduced capacity.&nbsp;&nbsp;Until these referral sources are at full capacity, we believe the COVID-19 pandemic will continue to affect the demand for DME products and Retail and Institutional Pharmacy drugs and products. Reductions in employee hours have been made in response to the lower demand. Nursing homes and other customers of such Institutional Pharmacy services are currently being adversely affected by the continuation of the COVID-19 pandemic, and this may be expected to have a further negative effect on such demand.&nbsp;&nbsp;Our Institutional Pharmacy services have experienced increased costs and operational inefficiencies due to measures taken to protect our employees and by access controls and other restrictions implemented by our institutional customers. The impact of the COVID-19 pandemic has negatively affected our supply processes, especially with respect to access to respiratory equipment and certain personal protective equipment and cleaning products. We believe the effect of the COVID&#8211;19 pandemic and certain public and governmental responses to it have negatively affected our last five fiscal quarters results.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.91%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the period from April 1, 2020 to March 31, 2021, our <font style="color:#212529;">Healthcare and Pharmacy segments received $5,070 in general and targeted Provider Relief Fund (&#8220;PRF&#8221;) distributions. During the quarter ended June 30, 2020, we also received $3,234 in Paycheck Protection Programs (&#8220;PPP&#8221;) loans, administered by the SBA. Both the PRF and PPP funds are provided for under the CARES Act and we have received a total of $8,304 of such funding.</font></p> <p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:3.91%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.24%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distributions from the PRF are not subject to repayment provided we are able to attest to and comply with the terms and conditions of the funding, including demonstrating that the funds received have been used for designated, allowable healthcare-related expenses and capital expenditures attributable to COVID-19,&nbsp;&nbsp;and for &#8220;Lost Revenues&#8221; (as defined by HHS). Such PRF are accounted for as government grants and are recognized on a systematic and rational basis once there is reasonable assurance that the applicable terms and conditions required to retain the funds have been met. HHS has released &#8220;CARES Act Provider Relief Fund Frequently Asked Questions (&#8220;FAQ&#8221;) numerous times since April 3, 2020 to clarify PRF requirements and has provided expansive examples of the reporting requirements in efforts to demonstrate amounts of the PRF received that may be considered to have been earned and which may be retained. The Company continues to review and analyze the FAQ. Of the $5,070 of PRF COVID-19 related distributions received during the period from April 1, 2020 through March 31, 2021,&nbsp;&nbsp;we have reported $3,459 as other income in our consolidated statement of operations for our nine months ended March 31, 2021 related to COVID-19 related expenses and Lost Revenues. Our uses of PRF consisted of COVID-19 personal protective equipment, allowable capital expenditures and salary expenses for allowable patient care activities. The Lost Revenues were calculated as the reduction of patient care revenues in calendar 2020 compared to the calendar 2020 budget and to actual patient care revenues of calendar 2019 in accordance with the latest guidance from HHS.&nbsp;&nbsp;Based upon the current HHS guidance, at the end of the quarter ended June 30, 2021, we will calculate the change of patient revenues for the period of January 1, 2021 to June 30, 2021 compared to the actual patient care revenue of the period January 1, 2020 to June 30, 2020. If the period January 1, 2021 to June 30, 2021 is less than the same period for calendar 2020, the decrease is eligible to be recognized as Lost Revenue in the quarter ended June&nbsp;&nbsp;30, 2021. The unrecognized amounts of the PRF are recorded under the caption &#8220;Unearned CARES Act Funds&#8221; in our consolidated balance sheets. We will continue to monitor compliance with the terms and conditions of the PRF and the impact of the pandemic on our revenues and expenses. If we are unable to attest to or comply with current or future terms and conditions, and there is no assurance we will be able to do so, our ability to retain some or all of the PRF received may be impacted and we and may have to return the unutilized portion of those funds, if any, in the future. </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.91%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Forgiveness of PPP loans may be available if the loans were used to pay wages, rent, utilities, and interest on certain debt during the eight-week period following receipt of the loan proceeds subject, to Federally-established terms and conditions.&nbsp;&nbsp;During July 2020, the allowable period for the use of PPP loan proceeds was amended to allow for a 24-week utilization period. The borrowing subsidiaries must apply for loan forgiveness with the lending bank within ten months after the end of the allowable use period. The forgiveness applications are to be reviewed by both the lender and the SBA and a loan forgiveness amount, if any, determined. There can be no assurance, however, that any of the PPP loans to us will be forgiven, or if forgiven, the amount of such forgiveness. Loan proceeds not forgiven are payable over two years at a 1% annual interest rate. The two-year loan repayment begins two months after the loan forgiveness amount is determined by SBA. The Company has applied for (but has not received) forgiveness for $287 of its $3,234 of PPP loans and has recorded no income relating to the PPP loans through March 31, 2021.</p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.91%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Going forward, the Company is unable to determine the extent to which the COVID-19 pandemic will continue to affect its assets and operations. Our ability to make estimates of the effect of the COVID-19 pandemic on revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is currently limited.&nbsp;&nbsp;The nature and extent of the effect of the COVID-19 pandemic on our balance sheet and results of operations will depend on: the severity and length of the pandemic; government actions to mitigate the pandemic&#8217;s effect; regulatory changes in response to the pandemic, especially those that affect our hospital, nursing home and pharmacy operations; existing and potential government assistance that may be provided; and the requirements of&nbsp;&nbsp;PRF receipts and PPP loans, including our ability to retain such PRF received and obtain forgiveness of the PPP Loans. </p> <p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:3.91%;color:#212529;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that existing funds, cash generated from operations and additional sources of and access to financing from COVID-19 related government loans and grants will likely be adequate to satisfy our needs for working capital and capital expenditures in the next twelve months. However, if the COVID-19 pandemic continues for an extended period, or if we are unable to retain PRF funds received and obtain forgiveness of the PPP Loans, we expect to experience significant losses and additional financial assistance will likely be required. <font style="color:#000000;">&#160;</font></p>
CY2020Q1 us-gaap Assets
Assets
22274000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
336000
ssy Operating Cash Flows From Finance Lease
OperatingCashFlowsFromFinanceLease
7000
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
9000
CY2020Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
8000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
21000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
15000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2021Q1 ssy Disposal Group Including Discontinued Operation Revenue Net Of Expenses
DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses
3000
CY2020Q1 ssy Disposal Group Including Discontinued Operation Revenue Net Of Expenses
DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses
-11000
ssy Disposal Group Including Discontinued Operation Revenue Net Of Expenses
DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses
1000
ssy Disposal Group Including Discontinued Operation Revenue Net Of Expenses
DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses
26000
CY2021Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-58000
CY2020Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-112000
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-179000
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-475000
CY2021Q1 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0
CY2020Q1 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
60000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
20732
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
87534
ssy Share Repurchase Average Price Per Share Paid
ShareRepurchaseAveragePricePerSharePaid
1.15
ssy Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
69000
ssy Health Care Organization Significant Change In Estimates
HealthCareOrganizationSignificantChangeInEstimates
107000
CY2021Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1272000
CY2020Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1401000
CY2021Q1 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
2060000
CY2020Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
1957000
CY2021Q1 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-62000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7000
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
29000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
21000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
87000
CY2021Q1 us-gaap Capital Lease Obligations
CapitalLeaseObligations
98000
CY2020Q2 us-gaap Capital Lease Obligations
CapitalLeaseObligations
124000
ssy Operating Variable Lease Cost
OperatingVariableLeaseCost
2000
ssy Operating Variable Lease Cost
OperatingVariableLeaseCost
2000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
136000
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
157000
CY2020Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
34000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-47000
CY2021Q1 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-62000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-47000
ssy Taxable Income Under Cares Act
TaxableIncomeUnderCARESAct
485000
CY2021Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8445000
CY2021Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
19017000
ssy Net Operating Loss Carry Forwards Expire Period
NetOperatingLossCarryForwardsExpirePeriod
2023 through fiscal 2038
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
127000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
147000
us-gaap Operating Lease Cost
OperatingLeaseCost
387000
us-gaap Operating Lease Cost
OperatingLeaseCost
437000
CY2021Q1 ssy Short Term Lease Cost Reversal
ShortTermLeaseCostReversal
8000
CY2020Q1 ssy Short Term Lease Cost Reversal
ShortTermLeaseCostReversal
9000
ssy Short Term Lease Cost Reversal
ShortTermLeaseCostReversal
37000
ssy Short Term Lease Cost Reversal
ShortTermLeaseCostReversal
24000
CY2021Q1 ssy Operating Variable Lease Cost
OperatingVariableLeaseCost
1000
CY2020Q1 ssy Operating Variable Lease Cost
OperatingVariableLeaseCost
1000
us-gaap Operating Lease Expense
OperatingLeaseExpense
426000
us-gaap Operating Lease Expense
OperatingLeaseExpense
463000
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
9000
CY2020Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
9000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
27000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
27000
CY2021Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
CY2020Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
6000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
7000
CY2021Q1 ssy Finance Lease Cost
FinanceLeaseCost
11000
CY2020Q1 ssy Finance Lease Cost
FinanceLeaseCost
11000
ssy Finance Lease Cost
FinanceLeaseCost
33000
ssy Finance Lease Cost
FinanceLeaseCost
34000
CY2021Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
203000
CY2020Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
203000
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentNet
CY2020Q2 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentNet
CY2021Q1 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
64000
CY2020Q2 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
43000
CY2021Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
36000
CY2021Q1 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:LongTermDebtCurrent
CY2020Q2 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:LongTermDebtCurrent
CY2021Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
62000
CY2020Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
90000
CY2021Q1 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:LongTermDebtNoncurrent
CY2020Q2 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:LongTermDebtNoncurrent
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
123000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
148000
us-gaap Operating Lease Payments
OperatingLeasePayments
383000
us-gaap Operating Lease Payments
OperatingLeasePayments
437000
CY2021Q1 ssy Operating Cash Flows From Finance Lease
OperatingCashFlowsFromFinanceLease
2000
CY2020Q1 ssy Operating Cash Flows From Finance Lease
OperatingCashFlowsFromFinanceLease
2000
ssy Operating Cash Flows From Finance Lease
OperatingCashFlowsFromFinanceLease
6000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
26000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
24000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
712000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1463000
CY2021Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M24D
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M28D
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M28D
CY2020Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M26D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0340
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0654
CY2021Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0654
CY2020Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0556
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
468000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
267000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
250000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
243000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
189000
CY2021Q1 ssy Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
13000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1430000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
87000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1343000
CY2021Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
42000
CY2021Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
42000
CY2021Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
25000
CY2021Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0
CY2021Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2021Q1 ssy Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
0
CY2021Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
109000
CY2021Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
11000
CY2021Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
98000
ssy Number Of Taxing Authorities
NumberOfTaxingAuthorities
2
CY2019Q4 us-gaap Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
359000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
299000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1299000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
884000

Files In Submission

Name View Source Status
0001564590-21-027833-index-headers.html Edgar Link pending
0001564590-21-027833-index.html Edgar Link pending
0001564590-21-027833.txt Edgar Link pending
0001564590-21-027833-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g3fu30j3gbzz000001.jpg Edgar Link pending
g3fu30j3gbzz000002.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ssy-10q_20210331.htm Edgar Link pending
ssy-20210331.xml Edgar Link completed
ssy-20210331.xsd Edgar Link pending
ssy-20210331_cal.xml Edgar Link unprocessable
ssy-20210331_def.xml Edgar Link unprocessable
ssy-20210331_lab.xml Edgar Link unprocessable
ssy-20210331_pre.xml Edgar Link unprocessable
ssy-ex311_7.htm Edgar Link pending
ssy-ex312_6.htm Edgar Link pending
ssy-ex321_8.htm Edgar Link pending
ssy-ex322_9.htm Edgar Link pending
ssy-ex3i_289.htm Edgar Link pending